



Australian Government

Department of Health, Disability and Ageing Therapeutic Goods Administration

Aspen Pharmacare Australia Pty Ltd – NERVODERM® lidocaine (lignocaine) 5% w/w dermal patch (ARTG 280081)

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by Aspen Pharmacare Australia Pty Ltd

I, Rowena Love, as a delegate of the Secretary to the Department of Health, Disability and Ageing, on receipt of an application from Aspen Pharmacare Australia Pty Ltd, have approved under section 42DF of the *Therapeutic Goods Act 1989*, the restricted representations described in paragraph (A), for use in advertisements for the product identified in paragraph (B)

(A)

- Nervoderm relieves medically diagnosed post-shingles pain
- Nervoderm relieves medically diagnosed persistent nerve pain following shingles
- Nervoderm relieves medically diagnosed post-shingles nerve pain
- Nervoderm relieves medically diagnosed post-shingles nerve pain (also known as post-herpetic neuralgia); and/or
- Nervoderm relieves pain associated with medically diagnosed post-shingles pain (also known as post-herpetic neuralgia).

(B)

- NERVODERM® lidocaine (lignocaine) 5% w/w dermal patch (ARTG 280081)

Dated this 17th day of August 2026

Signed electronically

Rowena Love

Delegate of the Secretary to the Department of Health, Disability and Ageing

Education Policy and Guidance Section

Regulatory Compliance Branch